Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia
Latest Information Update: 10 Sep 2024
At a glance
- Drugs Anti-CD7 chimeric antigen receptor T cell therapy-Yake Biotechnology (Primary)
- Indications Leukaemia
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2024 New trial record